• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-World Effectiveness, Safety, and Drug Survival of Risankizumab in Adult Patients with Plaque Psoriasis: A 3-Year Multicenter Retrospective Cohort Study.

作者信息

Torres Tiago, João Ana Luísa, Luz Martim, Mendes-Bastos Pedro, Roda Ângela, Leite Luiz, Valério Joana, Ferreirinha Ana, Leal Barbara, Paiva Lopes Maria João, Pimenta Rita, Ferreira Paulo

机构信息

Department of Dermatology, Centro Académico Clínico ICBAS/Santo António, Porto, Portugal.

Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.

出版信息

Am J Clin Dermatol. 2025 May 24. doi: 10.1007/s40257-025-00951-x.

DOI:10.1007/s40257-025-00951-x
PMID:40413337
Abstract
摘要

相似文献

1
Real-World Effectiveness, Safety, and Drug Survival of Risankizumab in Adult Patients with Plaque Psoriasis: A 3-Year Multicenter Retrospective Cohort Study.司库奇尤单抗在成人斑块状银屑病患者中的真实世界有效性、安全性及药物留存率：一项为期3年的多中心回顾性队列研究
Am J Clin Dermatol. 2025 May 24. doi: 10.1007/s40257-025-00951-x.
2
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS).司库奇尤单抗在真实世界环境中的有效性、耐受性和药物留存率：一项为期三年的回顾性多中心研究-IL PSO（意大利银屑病概况）
J Clin Med. 2024 Jan 16;13(2):495. doi: 10.3390/jcm13020495.
3
Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort study.司库奇尤单抗在成年斑块状银屑病患者中的真实世界有效性和安全性：一项为期1年的国际多中心回顾性队列研究。
J Am Acad Dermatol. 2024 Sep;91(3):513-515. doi: 10.1016/j.jaad.2024.03.048. Epub 2024 Apr 25.
4
Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 16-Week International Multicenter Retrospective Cohort Study.司库奇尤单抗在成人斑块状银屑病患者中的真实世界有效性和安全性：一项为期16周的国际多中心回顾性队列研究。
J Cutan Med Surg. 2024 Nov-Dec;28(6):604-605. doi: 10.1177/12034754241274300. Epub 2024 Sep 3.
5
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.司库奇尤单抗在银屑病患者中的真实世界安全性和有效性：一项多中心、回顾性、非干预性研究
Actas Dermosifiliogr. 2025 Feb;116(2):125-133. doi: 10.1016/j.ad.2024.02.030. Epub 2024 Mar 6.
6
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).IL-12/23、IL-17和IL-23抑制剂用于中重度斑块状银屑病的药物留存率：一项关于5932个治疗疗程的回顾性多中心真实世界研究——IL PSO（意大利银屑病概况）
Front Immunol. 2024 Jan 11;14:1341708. doi: 10.3389/fimmu.2023.1341708. eCollection 2023.
7
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study.司库奇尤单抗治疗131例中重度斑块状银屑病患者的真实疗效及安全性：一项52周回顾性研究
Dermatol Ther (Heidelb). 2022 Oct;12(10):2309-2324. doi: 10.1007/s13555-022-00795-x. Epub 2022 Sep 5.
8
Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months.司库奇尤单抗治疗中重度银屑病患者的真实世界疗效：VALUE全球上市后前瞻性观察性研究25个月的中期分析
Dermatol Ther (Heidelb). 2025 Feb;15(2):381-394. doi: 10.1007/s13555-025-01342-0. Epub 2025 Feb 4.
9
Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class.近期古塞库单抗治疗失败的斑块状银屑病患者中瑞莎珠单抗的真实世界有效性和安全性：一项白细胞介素-23抑制剂类药物转换的多中心回顾性研究
JAAD Int. 2023 May 26;12:136-138. doi: 10.1016/j.jdin.2023.05.006. eCollection 2023 Sep.
10
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers.利纳西珠单抗治疗难治性部位斑块状银屑病的疗效：来自两个转诊中心的真实世界经验。
J Dermatolog Treat. 2023 Dec;34(1):2220849. doi: 10.1080/09546634.2023.2220849.

本文引用的文献

1
Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis.158例中度至重度斑块状银屑病患者使用司库奇尤单抗2年期间的真实世界疗效、药物留存率及安全性
J Eur Acad Dermatol Venereol. 2025 Jan;39(1):e1-e4. doi: 10.1111/jdv.19956. Epub 2024 Mar 20.
2
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.司库奇尤单抗在银屑病患者中的真实世界安全性和有效性：一项多中心、回顾性、非干预性研究
Actas Dermosifiliogr. 2025 Feb;116(2):125-133. doi: 10.1016/j.ad.2024.02.030. Epub 2024 Mar 6.
3
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS).
通过长期真实观察-IL PSO（意大利银屑病情况）确定的司库奇尤单抗超级应答者特征
J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e113-e116. doi: 10.1111/jdv.19464. Epub 2023 Aug 29.
4
Introduction to real-world evidence studies.真实世界证据研究导论。
Perspect Clin Res. 2021 Jul-Sep;12(3):171-174. doi: 10.4103/picr.picr_62_21. Epub 2021 Jul 7.
5
Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort.性别在系统性银屑病治疗中的作用：BIOBADADERM前瞻性队列研究中的处方、有效性及安全性差异
Acta Derm Venereol. 2021 Jan 4;101(1):adv00354. doi: 10.2340/00015555-3711.
6
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.里莎努单抗：中重度斑块状银屑病的治疗药物评价。
Drugs. 2020 Aug;80(12):1235-1245. doi: 10.1007/s40265-020-01357-1.
7
Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results.生物银屑病疗法临床试验中缺失疗效数据的填补方法：对试验结果解读的影响
J Drugs Dermatol. 2017 Aug 1;16(8):734-741.